Atorvastatin News and Research

RSS
Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck's NOXAFIL injection gets FDA approval for intravenous use

High-potency statins offer improved chance of survival in heart attack patients

High-potency statins offer improved chance of survival in heart attack patients

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck announces approval of NOXAFIL delayed-release tablets by FDA

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Atorvastatin drug plus zoledronic acid may help treat toxoplasmosis

Atorvastatin drug plus zoledronic acid may help treat toxoplasmosis

High-dose statins could have added benefit of reducing gum inflammation

High-dose statins could have added benefit of reducing gum inflammation

Research shows commonly prescribed statin medicines can adversely affect cognitive function

Research shows commonly prescribed statin medicines can adversely affect cognitive function

Study: Atorvastatin reduces inflammation, thrombogenesis in patients with acute ischemic stroke

Study: Atorvastatin reduces inflammation, thrombogenesis in patients with acute ischemic stroke

Experimental agent fails to increase HDL levels, reveals new study

Experimental agent fails to increase HDL levels, reveals new study

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Reimbursement systems appear to impact on achievement of cholesterol lowering targets

Reimbursement systems appear to impact on achievement of cholesterol lowering targets

Study finds that high potency statins can beat dementia

Study finds that high potency statins can beat dementia

Genetic variations in genes could put patients at risk for statin-associated muscle injury: Study

Genetic variations in genes could put patients at risk for statin-associated muscle injury: Study

Stopping cholesterol drugs may increase risk of Parkinson's disease

Stopping cholesterol drugs may increase risk of Parkinson's disease

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

FDA accepts Merck's NDA for NOXAFIL tablets

FDA accepts Merck's NDA for NOXAFIL tablets